PR Newswire
NEW YORK, July 13, 2023
NEW YORK, July 13, 2023 /PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced an investigation of Biomea Fusion, Inc. ("Biomea Fusion") (NASDAQ: BMEA) concerning possible violations of federal securities laws.
On June 23, 2023, Biomea Fusion presented data for its Type 2 diabetes drug candidate BMF-219 at a meeting of the American Diabetes Association. In response to the presentation, market analysts downgraded Biomea Fusion and its stock price fell $6.25 per share, from $30.67 per share on June 23, 2023 to close at $24.42 per share on June 26, 2023.. To obtain additional information, go to:
https://zlk.com/pslra-1/biomea-fusion-lawsuit-submission-form?prid=42041&wire=4
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500.
WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
55 Broadway, 4th Floor Suite #427
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/bmea-investor-alert-levi--korsinsky-llp-notifies-investors-of-an-investigation-involving-possible-securities-fraud-violations-by-officers-of-biomea-fusion-inc-301876018.html
SOURCE Levi & Korsinsky, LLP
